Mayne Pharma launches BAC capsules

Press enter to search
Close search
Open Menu
A pharmacy stock room.

Mayne Pharma launches BAC capsules

By Sandra Levy - 05/22/2020

Mayne Pharma is releasing butalbital, acetaminophen and caffeine, or BAC, capsules. The product is indicated for the treatment of migraine.

Mayne Pharma's BAC capsules are available in a dosage strength of 500 mg butalbital, 300 mg acetaminophen and 40 mg of caffeine. 

“This launch complements our existing butalbital product range that includes a variety of dosage forms, strengths and combinations," said Scott Richards, CEO of Mayne Pharma. "Mayne Pharma continues to expand its product portfolio through internal product development, strategic alliances with best-in-class pharmaceutical developers and manufacturers and other business development activities."

BAC capsules 500 mg/300 mg/40 mg had a market value of approximately $40 million for the 12 months ended March 31, 2020, according to IQVIA.

Related Topics